495 lines
31 KiB
HTML
495 lines
31 KiB
HTML
<!DOCTYPE html>
|
||
<html lang="zh-CN" data-theme="night">
|
||
<head>
|
||
<meta charset="UTF-8">
|
||
<meta name="viewport" content="width=device-width, initial-scale=1.0">
|
||
<title>医药外包CXO 深度投研报告</title>
|
||
<script src="https://cdn.tailwindcss.com"></script>
|
||
<link href="https://cdn.jsdelivr.net/npm/daisyui@4.11.1/dist/full.min.css" rel="stylesheet" type="text/css" />
|
||
<script defer src="https://cdn.jsdelivr.net/npm/alpinejs@3.x.x/dist/cdn.min.js"></script>
|
||
<script src="https://cdn.jsdelivr.net/npm/echarts@5.5.0/dist/echarts.min.js"></script>
|
||
<style>
|
||
@import url('https://fonts.googleapis.com/css2?family=Noto+Sans+SC:wght@300;400;500;700&display=swap');
|
||
|
||
body {
|
||
font-family: 'Noto Sans SC', sans-serif;
|
||
background-color: #020024;
|
||
background-image:
|
||
radial-gradient(ellipse at top, rgba(13, 110, 253, 0.2) 0%, rgba(13, 110, 253, 0) 50%),
|
||
radial-gradient(ellipse at bottom, rgba(111, 66, 193, 0.2) 0%, rgba(111, 66, 193, 0) 50%),
|
||
linear-gradient(to right, #000428, #000000);
|
||
background-attachment: fixed;
|
||
color: #E0E0E0;
|
||
}
|
||
|
||
.glass-card {
|
||
background: rgba(20, 20, 50, 0.3);
|
||
backdrop-filter: blur(20px);
|
||
-webkit-backdrop-filter: blur(20px);
|
||
border-radius: 24px;
|
||
border: 1px solid rgba(255, 255, 255, 0.1);
|
||
transition: all 0.3s ease;
|
||
box-shadow: 0 8px 32px 0 rgba(0, 0, 0, 0.37);
|
||
}
|
||
|
||
.glass-card:hover {
|
||
transform: translateY(-5px) scale(1.01);
|
||
box-shadow: 0 0 40px rgba(76, 126, 255, 0.3), 0 0 20px rgba(111, 66, 193, 0.2);
|
||
border-color: rgba(255, 255, 255, 0.2);
|
||
}
|
||
|
||
.fui-title {
|
||
text-shadow: 0 0 10px rgba(0, 191, 255, 0.7), 0 0 20px rgba(0, 191, 255, 0.5);
|
||
letter-spacing: 0.1em;
|
||
}
|
||
|
||
.bento-grid {
|
||
display: grid;
|
||
gap: 1rem;
|
||
grid-template-columns: repeat(12, 1fr);
|
||
}
|
||
|
||
.bento-item {
|
||
grid-column: span 12;
|
||
}
|
||
|
||
@media (min-width: 768px) {
|
||
.bento-item-1 { grid-column: span 8; grid-row: span 2; }
|
||
.bento-item-2 { grid-column: span 4; }
|
||
.bento-item-3 { grid-column: span 4; }
|
||
.bento-item-4 { grid-column: span 6; }
|
||
.bento-item-5 { grid-column: span 6; }
|
||
}
|
||
|
||
@media (min-width: 1024px) {
|
||
.bento-item-1 { grid-column: span 6; grid-row: span 2; }
|
||
.bento-item-2 { grid-column: span 6; }
|
||
.bento-item-3 { grid-column: span 4; }
|
||
.bento-item-4 { grid-column: span 4; grid-row: span 1;}
|
||
.bento-item-5 { grid-column: span 4; grid-row: span 1;}
|
||
}
|
||
|
||
.text-glow {
|
||
text-shadow: 0 0 8px currentColor;
|
||
}
|
||
|
||
.prose h3 {
|
||
color: #93c5fd;
|
||
}
|
||
.prose h4 {
|
||
color: #a5b4fc;
|
||
margin-top: 1em;
|
||
margin-bottom: 0.5em;
|
||
}
|
||
.prose strong {
|
||
color: #fde047;
|
||
}
|
||
.prose ul > li::before {
|
||
background-color: #60a5fa;
|
||
}
|
||
.prose {
|
||
color: #d1d5db;
|
||
}
|
||
</style>
|
||
</head>
|
||
<body class="antialiased min-h-screen">
|
||
<div class="container mx-auto p-4 md:p-8">
|
||
|
||
<!-- Header -->
|
||
<header class="text-center mb-12">
|
||
<h1 class="text-4xl md:text-6xl font-bold fui-title text-cyan-300 tracking-wider">医药外包CXO 深度投研报告</h1>
|
||
<p class="mt-4 text-lg text-gray-400">北京价值前沿科技有限公司 AI投研agent：“价小前投研”</p>
|
||
<div class="divider divider-primary before:bg-blue-500/30 after:bg-purple-500/30"></div>
|
||
<p class="text-sm text-gray-500">本报告为AI合成数据，不构成任何投资建议，投资需谨慎。</p>
|
||
</header>
|
||
|
||
<!-- Concept Events Timeline Chart -->
|
||
<section class="mb-12">
|
||
<div class="glass-card p-6">
|
||
<h2 class="text-2xl font-bold mb-4 text-blue-300">概念关键事件演进</h2>
|
||
<div id="timeline-chart" class="w-full h-80"></div>
|
||
</div>
|
||
</section>
|
||
|
||
<!-- Core Insight Section -->
|
||
<section class="mb-12">
|
||
<div class="bento-grid">
|
||
<!-- Core Logic & View -->
|
||
<div class="bento-item bento-item-1 glass-card p-6 flex flex-col">
|
||
<h2 class="text-2xl font-bold mb-4 text-blue-300">核心观点与逻辑</h2>
|
||
<div class="prose max-w-none flex-grow">
|
||
<h3>核心观点摘要</h3>
|
||
<p>医药外包CXO概念正处于一个由<strong>政策风险缓和</strong>与<strong>全球投融资触底</strong>共同驱动的关键<strong>估值与业绩双击的拐点</strong>。其核心驱动力正从过去依赖成本优势的“全球产能替代”，升级为以技术平台赋能全球创新的“中国引擎”角色。未来，行业的增长潜力将更多体现在如ADC、多肽等高附加值新兴领域的结构性机会，以及龙头企业全球化布局带来的市场份额提升。</p>
|
||
<h3>核心驱动力</h3>
|
||
<ol>
|
||
<li><strong>全球产业链刚需与成本效率优势</strong>：全球药企为降本增效，持续提升研发生产外包渗透率（现有<strong>约40%</strong>，目标<strong>50%</strong>以上）。中国CXO企业凭借工程师红利带来的成本与效率优势，在全球产业链中仍具备不可替代性。</li>
|
||
<li><strong>技术迭代催生的增量需求</strong>：行业已进入“技术赋能”新纪元。ADC、多肽/寡核苷酸（TIDES）、AI药物发现等新兴技术领域壁垒高、产能稀缺，驱动了更高附加值的外包需求。例如，药明康德TIDES业务收入<strong>同比增长141.6%</strong>，九洲药业化学大分子在手订单<strong>同比+130%</strong>以上。</li>
|
||
<li><strong>政策周期与融资环境的共振</strong>：美国《生物安全法案》风险的边际改善解除了最大外部压制，而美联储降息预期则有望开启新一轮全球生物医药投融资上行周期，构成戴维斯双击（估值与业绩双升）的基础。</li>
|
||
</ol>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- Market Heat & Expectation Gap -->
|
||
<div class="bento-item bento-item-2 glass-card p-6">
|
||
<h2 class="text-2xl font-bold mb-4 text-blue-300">市场热度与预期差</h2>
|
||
<div class="prose max-w-none">
|
||
<h3>市场热度与情绪</h3>
|
||
<p>当前市场对CXO概念的关注度极高，情绪已从前期的极度悲观转向<strong>普遍乐观</strong>。“拐点已现”、“历史底部”、“积极配置”等词语高频出现，显示卖方机构观点高度一致。政策利好或龙头业绩超预期能迅速点燃整个板块。</p>
|
||
<h3>预期差分析</h3>
|
||
<ul>
|
||
<li><strong>盈利修复的非同步性</strong>：市场可能高估了收入复苏传导至利润复苏的速度。临床CRO领域存在激烈价格战（折扣从8折降至<strong>4-8折</strong>），毛利率修复可能滞后。</li>
|
||
<li><strong>内需与外需的温差</strong>：海外需求复苏迹象比国内更明确。国内生物医药投融资仍处“政策托底”阶段，复苏力度相对较弱。</li>
|
||
<li><strong>龙头与中小企业的分化</strong>：行业出清阶段，资源将向头部企业加速集中，并非所有CXO公司都能同等受益。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- Catalysts -->
|
||
<div class="bento-item bento-item-3 glass-card p-6">
|
||
<h2 class="text-2xl font-bold mb-4 text-blue-300">关键催化剂</h2>
|
||
<div class="prose max-w-none">
|
||
<h4>近期催化剂 (3-6个月)</h4>
|
||
<ul>
|
||
<li><strong>美联储降息周期开启</strong>：促进生物医药投融资回暖的最强宏观催化剂。</li>
|
||
<li><strong>国内创新药全产业链支持政策</strong>：市场对此有较强预期，将直接提振国内景气度。</li>
|
||
<li><strong>龙头公司持续超预期的季报</strong>：如药明康德中报已成“强心针”，将巩固市场信心。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- Future Path -->
|
||
<div class="bento-item bento-item-4 glass-card p-6">
|
||
<h2 class="text-2xl font-bold mb-4 text-blue-300">长期发展路径</h2>
|
||
<div class="prose max-w-none">
|
||
<ul>
|
||
<li><strong>从“成本替代”到“技术赋能”</strong>：成为全球创新的深度参与者和赋能者。</li>
|
||
<li><strong>全球化布局深化（Local for Local）</strong>：在欧美建设本土化基地，增强供应链韧性。</li>
|
||
<li><strong>一体化平台优势凸显</strong>：“一站式”服务能力成核心竞争力，行业“马太效应”加剧。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- Risks -->
|
||
<div class="bento-item bento-item-5 glass-card p-6">
|
||
<h2 class="text-2xl font-bold mb-4 text-red-400">潜在风险与挑战</h2>
|
||
<div class="prose max-w-none">
|
||
<ul>
|
||
<li><strong class="text-red-300">地缘政治风险</strong>：《生物安全法案》风险虽缓和但未消失，是悬顶之剑。</li>
|
||
<li><strong class="text-red-300">行业内卷加剧</strong>：价格竞争可能长期侵蚀行业利润。</li>
|
||
<li><strong class="text-red-300">投融资复苏不及预期</strong>：宏观经济不确定性影响下游需求。</li>
|
||
<li><strong class="text-red-300">信息交叉验证风险</strong>：收入增长与利润增长可能脱节，机构持仓已现分化。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
|
||
<!-- Industry Chain & Core Companies -->
|
||
<section class="mb-12">
|
||
<div class="glass-card p-6">
|
||
<h2 class="text-2xl font-bold mb-4 text-blue-300">产业链与核心公司深度剖析</h2>
|
||
<div class="prose max-w-none">
|
||
<h4>产业链图谱</h4>
|
||
<div class="flex flex-col md:flex-row justify-around items-center space-y-4 md:space-y-0 md:space-x-4 my-6">
|
||
<div class="text-center p-4 border border-cyan-500/50 rounded-xl shadow-lg shadow-cyan-500/20">
|
||
<p class="font-bold text-lg text-cyan-300">上游</p>
|
||
<p class="text-sm">分子砌块、试剂、模式动物</p>
|
||
<p class="text-xs mt-1">(毕得医药, 药石科技, 药康生物)</p>
|
||
</div>
|
||
<div class="text-3xl text-gray-500 font-mono">>></div>
|
||
<div class="text-center p-4 border border-indigo-500/50 rounded-xl shadow-lg shadow-indigo-500/20">
|
||
<p class="font-bold text-lg text-indigo-300">中游 (CXO核心)</p>
|
||
<p class="text-sm">临床前/临床CRO, CDMO/CMO</p>
|
||
<p class="text-xs mt-1">(药明康德, 泰格医药, 凯莱英)</p>
|
||
</div>
|
||
<div class="text-3xl text-gray-500 font-mono">>></div>
|
||
<div class="text-center p-4 border border-purple-500/50 rounded-xl shadow-lg shadow-purple-500/20">
|
||
<p class="font-bold text-lg text-purple-300">下游</p>
|
||
<p class="text-sm">全球Pharma & Biotech</p>
|
||
<p class="text-xs mt-1">(制药企业)</p>
|
||
</div>
|
||
</div>
|
||
<h4>核心玩家对比</h4>
|
||
<div class="grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-6 mt-6">
|
||
<!-- Player Card -->
|
||
<div class="bg-slate-800/30 p-4 rounded-xl border border-white/10">
|
||
<h5>领导者：药明康德</h5>
|
||
<p><strong>优势</strong>: 全球一体化龙头，订单增长强劲 (在手YOY <strong>35.2%+</strong>)，新兴领域(TIDES)布局领先，获基金<strong>大幅增持</strong>。</p>
|
||
<p><strong>风险</strong>: 地缘政治风险主要承担者，体量大增速或放缓。</p>
|
||
</div>
|
||
<!-- Player Card -->
|
||
<div class="bg-slate-800/30 p-4 rounded-xl border border-white/10">
|
||
<h5>追赶者：康龙化成</h5>
|
||
<p><strong>优势</strong>: 业务结构类似药明，稳健增长 (新签YOY <strong>18%+</strong>)，港股估值较低。</p>
|
||
<p><strong>风险</strong>: 规模与技术有差距，遭部分基金<strong>减持</strong>。</p>
|
||
</div>
|
||
<!-- Player Card -->
|
||
<div class="bg-slate-800/30 p-4 rounded-xl border border-white/10">
|
||
<h5>细分龙头(临床CRO)：泰格医药</h5>
|
||
<p><strong>优势</strong>: 国内临床CRO绝对龙头，受益国内政策，订单好于预期 (净新增订单<strong>YoY+20%</strong>)。</p>
|
||
<p><strong>风险</strong>: <strong>面临激烈价格战</strong>，盈利能力短期承压，毛利率同比下降7.8ppt。</p>
|
||
</div>
|
||
<!-- Player Card -->
|
||
<div class="bg-slate-800/30 p-4 rounded-xl border border-white/10">
|
||
<h5>细分龙头(小分子CDMO)：凯莱英</h5>
|
||
<p><strong>优势</strong>: 技术领先，与大客户深度绑定，订单稳健 (新签<strong>+约20%</strong>)，欧美客户增速亮眼。</p>
|
||
<p><strong>风险</strong>: 依赖大客户订单，业绩存在波动性。</p>
|
||
</div>
|
||
<!-- Player Card -->
|
||
<div class="bg-slate-800/30 p-4 rounded-xl border border-white/10">
|
||
<h5>新兴王者(ADC CDMO)：药明合联</h5>
|
||
<p><strong>优势</strong>: 高景气赛道龙头，技术壁垒高，产能稀缺，业绩爆发式增长 (预计收入<strong>+85%</strong>, 利润<strong>+260%</strong>)。</p>
|
||
<p><strong>风险</strong>: 估值较高，市场预期充分。</p>
|
||
</div>
|
||
<!-- Verification -->
|
||
<div class="bg-green-900/30 p-4 rounded-xl border border-green-500/30 col-span-1 md:col-span-2 lg:col-span-3">
|
||
<h5 class="text-green-300">验证与证伪</h5>
|
||
<p><strong class="text-green-400">验证点</strong>: “订单复苏”逻辑在药明康德(+35.2%)、博腾股份(+40%)等公司数据中得到强力验证。ADC赛道高景气被药明合联业绩完美印证。</p>
|
||
<p><strong class="text-red-400">风险/证伪点</strong>: 盈利能力存在矛盾。路演数据揭示了临床CRO的“价格战”和利润率压力，泰格医药毛利率下滑印证了这一点，需警惕“增收不增利”。</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
|
||
<!-- Supporting Data Tabs -->
|
||
<section class="mb-12" x-data="{ tab: 'news' }">
|
||
<div class="glass-card p-6">
|
||
<div role="tablist" class="tabs tabs-bordered tabs-lg">
|
||
<a role="tab" class="tab" :class="{'tab-active': tab === 'news'}" @click="tab = 'news'">新闻数据</a>
|
||
<a role="tab" class="tab" :class="{'tab-active': tab === 'roadshow'}" @click="tab = 'roadshow'">路演纪要</a>
|
||
<a role="tab" class="tab" :class="{'tab-active': tab === 'research'}" @click="tab = 'research'">研报精粹</a>
|
||
</div>
|
||
<div class="prose max-w-none mt-6">
|
||
<!-- News Content -->
|
||
<div x-show="tab === 'news'">
|
||
<h4>核心观点与市场情绪</h4>
|
||
<ul>
|
||
<li><strong>整体判断</strong>: 经营改善，看好向上。多家机构认为行业有望步入上升周期，目前已处历史底部。</li>
|
||
<li><strong>拐点显现</strong>: 多家机构明确提出“拐点已现”，看好“板块底部布局机会”。</li>
|
||
<li><strong>市场表现</strong>: 港股CXO概念多次走强，海外同行(Medpace, IQVIA)业绩复苏，股价大涨。</li>
|
||
</ul>
|
||
<h4>经营基本面（订单强劲）</h4>
|
||
<ul>
|
||
<li><strong>药明康德</strong>: 25年3月末，在手订单同比增长<strong>47.1%</strong>。</li>
|
||
<li><strong>泰格医药</strong>: 25Q1净新增订单20亿元(YoY+20%)，好于预期。</li>
|
||
<li><strong>康龙化成</strong>: 24年新签订单+20%以上。</li>
|
||
<li><strong>博腾股份</strong>: 在手订单同比保持40%以上的增长。</li>
|
||
<li><strong>药明合联</strong>: 24年底在手订单同比+71%，预计24年收入增超85%。</li>
|
||
</ul>
|
||
<h4>政策与宏观环境</h4>
|
||
<ul>
|
||
<li><strong>美国《生物安全法案》</strong>: 未包含在NDAA妥协版本中，“夹带立法风险解除”，地缘政治影响减弱。</li>
|
||
<li><strong>全球投融资</strong>: 全球投融资渐触底，美联储降息预期将促进回暖。</li>
|
||
<li><strong>国内政策</strong>: 国务院发文“大力发展生物医药研发外包”，地方政策持续加码。</li>
|
||
</ul>
|
||
</div>
|
||
<!-- Roadshow Content -->
|
||
<div x-show="tab === 'roadshow'">
|
||
<h4>行业整体趋势与景气度</h4>
|
||
<ul>
|
||
<li><strong>行业周期</strong>: 经历三年调整（估值雪崩->杀业绩->法案扰动），进入估值底部区域。</li>
|
||
<li><strong>融资触底</strong>: 全球及中国医疗健康投融资规模趋于平稳，融资端已触底，拐点将至。</li>
|
||
<li><strong>竞争格局</strong>: 中小CXO低价抢单，但加速出清；头部企业市占率提升。临床板块价格战激烈。</li>
|
||
</ul>
|
||
<h4>上游需求与融资环境</h4>
|
||
<ul>
|
||
<li><strong>全球市场</strong>: 大型药企(Pharma)研发开支同比增长15%，支撑外包需求。外包渗透率持续提升（~40% -> 50%+）。</li>
|
||
<li><strong>国内市场</strong>: 融资仍承压，但IND申报热度不减，支撑CRO订单。</li>
|
||
</ul>
|
||
<h4>重点公司信息</h4>
|
||
<ul>
|
||
<li><strong>药明康德</strong>: 24年中报在手订单同比+33%，A股PE低于15倍。</li>
|
||
<li><strong>药明生物</strong>: 24年收入及利润目标双增15%，估值成“全球最低的龙头CXO”。</li>
|
||
<li><strong>泰格医药</strong>: PE低于15倍，PEG约0.6，性价比凸显，Q1新订单趋势向好。</li>
|
||
</ul>
|
||
</div>
|
||
<!-- Research Report Content -->
|
||
<div x-show="tab === 'research'">
|
||
<h4>核心事件驱动</h4>
|
||
<ul>
|
||
<li><strong>美国生物安全法案未被列入NDAA (2024-12-09)</strong>: 压制板块估值的主要因素得到缓解，“CXO板块有望迎来新一轮估值修复”。</li>
|
||
</ul>
|
||
<h4>行业观点与投资建议</h4>
|
||
<ul>
|
||
<li><strong>行业升级 (2025-07-15)</strong>: 中国CXO已从“成本替代”迈入“技术赋能”新纪元，成为全球医药创新的“中国引擎”。</li>
|
||
<li><strong>基金配置 (2025-01-25)</strong>: 24Q4基金对医疗研发外包配置占比1.40%，降幅趋缓。<strong>药明康德</strong>获基金大幅增持，<strong>康龙化成</strong>遭减持。</li>
|
||
<li><strong>核心标的</strong>: 药明康德、药明合联、泰格医药、凯莱英、康龙化成等龙头公司被密集推荐。</li>
|
||
</ul>
|
||
<h4>关键数据与趋势</h4>
|
||
<ul>
|
||
<li><strong>国内药企海外临床增长</strong>: 2019-2023年数量接近翻倍，驱动临床CRO需求。</li>
|
||
<li><strong>业绩验证</strong>: 药明康德2025年中期业绩预告强劲，验证了中国CXO平台的技术实力与全球化运营效率。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
|
||
<!-- Conclusion & Stock Data -->
|
||
<section class="mb-12">
|
||
<div class="glass-card p-4 md:p-6">
|
||
<h2 class="text-2xl font-bold mb-4 text-blue-300">相关个股异动分析</h2>
|
||
<div class="overflow-x-auto">
|
||
<table class="table table-zebra w-full">
|
||
<thead class="text-base text-gray-300">
|
||
<tr>
|
||
<th>股票名称</th>
|
||
<th>代码</th>
|
||
<th>涨跌幅</th>
|
||
<th>日期</th>
|
||
<th>异动原因摘要</th>
|
||
</tr>
|
||
</thead>
|
||
<tbody>
|
||
<!-- Data rows will be inserted here -->
|
||
<tr>
|
||
<td>普蕊斯</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=301257" target="_blank" class="link link-hover text-blue-400">301257</a></td>
|
||
<td><span class="text-error font-semibold">+17.55%</span></td>
|
||
<td>2025-07-09</td>
|
||
<td class="prose prose-sm max-w-none">创新药概念整体回暖，CXO方向领涨；中金研报看好中国创新药国际化竞争力，提升产业链信心；ASCO/ESMO等国际会议催化效应。</td>
|
||
</tr>
|
||
<tr>
|
||
<td>益诺思</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=688710" target="_blank" class="link link-hover text-blue-400">688710</a></td>
|
||
<td><span class="text-error font-semibold">+11.19%</span></td>
|
||
<td>2025-07-08</td>
|
||
<td class="prose prose-sm max-w-none">CXO/CRO板块整体强势反弹，受创新药BD交易频发、产业链景气度修复预期驱动；公司作为安评龙头，具备稀缺资质和国资背景优势。</td>
|
||
</tr>
|
||
<tr>
|
||
<td>凯莱英</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=002821" target="_blank" class="link link-hover text-blue-400">002821</a></td>
|
||
<td><span class="text-error font-semibold">+10.00%</span></td>
|
||
<td>2025-07-24</td>
|
||
<td class="prose prose-sm max-w-none">药监局“30日默示许可”新政利好CXO；外媒报道礼来追加15亿美元订单预期，作为礼来供应链核心企业，凯莱英率先受益。</td>
|
||
</tr>
|
||
<tr>
|
||
<td>睿智医药</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=300149" target="_blank" class="link link-hover text-blue-400">300149</a></td>
|
||
<td><span class="text-error font-semibold">+20.02%</span></td>
|
||
<td>2025-07-29</td>
|
||
<td class="prose prose-sm max-w-none">美国生物安全法案条款调整缓解地缘风险；公司ADC商业化产能翻倍，并与全球Top10药企签订3.8亿美元大单，基本面迎来重大利好。</td>
|
||
</tr>
|
||
<tr>
|
||
<td>药明康德</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=603259" target="_blank" class="link link-hover text-blue-400">603259</a></td>
|
||
<td><span class="text-error font-semibold">+7.95%</span></td>
|
||
<td>2025-08-29</td>
|
||
<td class="prose prose-sm max-w-none">医药股及CXO板块集体走强；AI+医药概念发酵，提升研发服务预期；主力资金大幅净流入12亿元，美国法案担忧缓解，投资者情绪改善。</td>
|
||
</tr>
|
||
<tr>
|
||
<td>药康生物</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=688046" target="_blank" class="link link-hover text-blue-400">688046</a></td>
|
||
<td><span class="text-error font-semibold">+7.99%</span></td>
|
||
<td>2025-07-29</td>
|
||
<td class="prose prose-sm max-w-none">受CXO行业景气度提升带动，龙头药明康德业绩超预期提振板块信心；作为产业链上游，受益于创新药研发热度提升。</td>
|
||
</tr>
|
||
<tr>
|
||
<td>毕得医药</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=688073" target="_blank" class="link link-hover text-blue-400">688073</a></td>
|
||
<td><span class="text-error font-semibold">+6.48%</span></td>
|
||
<td>2025-09-16</td>
|
||
<td class="prose prose-sm max-w-none">公司参与行业业绩说明会获市场关注；CXO领域景气度上行，获机构研报推荐；创新药产业链整体向好，带动上游分子砌块供应商。</td>
|
||
</tr>
|
||
<tr>
|
||
<td>康龙化成</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=300759" target="_blank" class="link link-hover text-blue-400">300759</a></td>
|
||
<td><span class="text-error font-semibold">+6.49%</span></td>
|
||
<td>2025-07-29</td>
|
||
<td class="prose prose-sm max-w-none">受益于医药外包板块集体上涨，特别是港股同行大涨的传导效应；A+H股联动，估值修复逻辑。</td>
|
||
</tr>
|
||
<tr>
|
||
<td>首药控股</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=688197" target="_blank" class="link link-hover text-blue-400">688197</a></td>
|
||
<td><span class="text-error font-semibold">+6.33%</span></td>
|
||
<td>2025-07-30</td>
|
||
<td class="prose prose-sm max-w-none">药明康德亮眼业绩带动CXO板块情绪，公司作为创新药研发企业受益；创新药研发环境积极，国际市场利好，板块资金回流。</td>
|
||
</tr>
|
||
<tr>
|
||
<td>皓元医药</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=688131" target="_blank" class="link link-hover text-blue-400">688131</a></td>
|
||
<td><span class="text-error font-semibold">+5.02%</span></td>
|
||
<td>2025-06-10</td>
|
||
<td class="prose prose-sm max-w-none">创新药与CRO概念板块整体活跃；公司在热门ADC领域的布局受关注；创新药投融资环境预期修复。</td>
|
||
</tr>
|
||
<tr>
|
||
<td>诺思格</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=301333" target="_blank" class="link link-hover text-blue-400">301333</a></td>
|
||
<td><span class="text-error font-semibold">+5.01%</span></td>
|
||
<td>2025-07-08</td>
|
||
<td class="prose prose-sm max-w-none">CRO/CXO行业整体走强，受行业基本面改善信号（BD交易频发）和机构推荐效应驱动。</td>
|
||
</tr>
|
||
</tbody>
|
||
</table>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
|
||
</div>
|
||
|
||
<script>
|
||
var chartDom = document.getElementById('timeline-chart');
|
||
var myChart = echarts.init(chartDom, 'dark');
|
||
var option;
|
||
|
||
const data = [
|
||
{ name: '行业下行周期', value: [new Date('2021-10-01'), 1], itemStyle: { color: '#5470c6' }, label: { formatter: '{b}\n估值雪崩\n杀业绩' } },
|
||
{ name: '地缘政治风险发酵', value: [new Date('2024-02-01'), 2], itemStyle: { color: '#fac858' }, label: { formatter: '{b}\n《生物安全法案》\n估值底部' } },
|
||
{ name: '拐点信号密集出现', value: [new Date('2024-11-01'), 3], itemStyle: { color: '#ee6666' }, label: { formatter: '{b}\n融资触底\n订单复苏' } },
|
||
{ name: '地缘政治风险缓和', value: [new Date('2024-12-09'), 4], itemStyle: { color: '#73c0de' }, label: { formatter: '{b}\n法案未入NDAA\n估值修复' } },
|
||
{ name: '基本面复苏确认', value: [new Date('2025-04-01'), 5], itemStyle: { color: '#91cc75' }, label: { formatter: '{b}\n政策支持\n业绩验证' } }
|
||
];
|
||
|
||
option = {
|
||
backgroundColor: 'transparent',
|
||
tooltip: {
|
||
trigger: 'axis',
|
||
formatter: function (params) {
|
||
const param = params[0];
|
||
const date = new Date(param.value[0]);
|
||
const dateString = date.getFullYear() + '-' + (date.getMonth() + 1);
|
||
return dateString + '<br/>' + param.marker + param.name;
|
||
},
|
||
axisPointer: {
|
||
animation: false
|
||
}
|
||
},
|
||
xAxis: {
|
||
type: 'time',
|
||
splitLine: { show: false },
|
||
axisLabel: { color: '#9ca3af' }
|
||
},
|
||
yAxis: {
|
||
type: 'value',
|
||
max: 6,
|
||
splitLine: { show: false },
|
||
axisLabel: { show: false },
|
||
axisLine: { show: false },
|
||
axisTick: { show: false }
|
||
},
|
||
grid: {
|
||
left: '3%',
|
||
right: '4%',
|
||
bottom: '3%',
|
||
containLabel: true
|
||
},
|
||
series: [{
|
||
type: 'scatter',
|
||
symbolSize: 30,
|
||
data: data,
|
||
label: {
|
||
show: true,
|
||
position: 'top',
|
||
color: '#e5e7eb',
|
||
fontSize: 12,
|
||
align: 'center'
|
||
}
|
||
}]
|
||
};
|
||
|
||
option && myChart.setOption(option);
|
||
window.addEventListener('resize', myChart.resize);
|
||
</script>
|
||
</body>
|
||
</html> |